John Patrick Shannon Jr.

Filings by John Patrick Shannon Jr. span 2 companies, the busiest being Xeris Biopharma Holdings, Inc. and Xeris Pharmaceuticals Inc. We count 45 filings; the first trade dates from 25 June 2018 and the latest from 1 August 2026.

Both buying and selling appear: 6 purchases worth €371k, against 2 sales worth €300k. Netting one side against the other leaves €71k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 29 share grants and 5 option exercises. 2026 to date brings no purchases and 1 sale.

In size, the median ticket on the buying side is €59k. Clusters matter here: 6 out of 6 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 21 August 2026, the filings show a share grant worth €257k in Xeris Biopharma Holdings, Inc. The last purchase on record was published on 17 November 2023, which is 1,071 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.